This page contains a Flash digital edition of a book.
BIOTECHNOLOGY 53


of the models. Understanding these mechanisms of response and resistance can provide predictive biomarkers and genetic signatures of response to a given agent, which delivers an important stratifying tool for the clinic. Leveraging these biomarkers and signatures to select patients for efficacy based, late-phase clinical trials provides the greatest likelihood of success of an agent in the clinic, and a reduction in the attrition rate for novel oncology therapies. PDX model data closely


resembles patient clinical response, and retrospective analyses have shown that


PDX models have a predictive power for tumour response to treatment. Each PDX model reflects the pathology of its original patient (behaving as a patient avatar), and the cohort of patient avatars represent a diversity of the human patient population. Analysis of avatar response can identify responder and non-responder populations, identifying which patients will benefit most from a given treatment, based on their genetic profile and that of their tumour. Establishing a responder population before entering clinical trials will allow better stratification of potential clinical


First frozen 3D cell-based assay now available


S


temTek Therapeutics has started serving Cell2Sphere ready to use 3D cell culture kits to researchers throughout the world.


Designed for drug discovery research in industrial, biotech,


pharma and academic fields, Cell2Sphere represents a geometric evolution in cell based assay development. Using a scaffold-free technology, 3D spheroid cells arrive frozen and grow in a standard 96 well ultra low-adhesion plate for use in molecular compound testing. Cell2Sphere is the first simple 3D tissue culture kit for


labs interested in more accurate, scalable and dynamic experimental research, the frozen spheroid tissue culture samples considerably increase the shelf life of today’s 3D cultures.


www.scientistlive.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76